Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GlucoWatch Recommendation Conditioned On Extensive Education Program

This article was originally published in The Gray Sheet

Executive Summary

Cygnus, Inc. should develop an "extensive education program" for both physicians and patients in the use of the firm's GlucoWatch Biographer wrist-worn semi-continuous glucose meter, members of FDA's Clinical Chemistry and Clinical Toxicology Devices Panel agreed Dec. 6 in Gaithersburg, Maryland.

You may also be interested in...



Cygnus GlucoWatch Pilot Marketing Program To Begin In April

Cygnus plans to kick off a pilot marketing program in April targeting 100-150 Type 1 diabetes patients to gauge firsthand consumer experience with the GlucoWatch Biographer. The non-invasive glucose monitoring system was approved by FDA on March 22.

Cygnus GlucoWatch Pilot Marketing Program To Begin In April

Cygnus plans to kick off a pilot marketing program in April targeting 100-150 Type 1 diabetes patients to gauge firsthand consumer experience with the GlucoWatch Biographer. The non-invasive glucose monitoring system was approved by FDA on March 22.

Cygnus Sizzles In June; Stock Rises 77% On Heels Of Diabetes Conference

The stock prices of diabetes product manufacturers Cygnus and MiniMed headed in opposite directions in the aftermath of the June 9-13 annual meeting of the American Diabetes Association.

Related Content

UsernamePublicRestriction

Register

MT012700

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel